Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $4.13 Consensus PT from Analysts

Lucid Diagnostics Inc. (NASDAQ:LUCD) has received an average recommendation of “Moderate Buy” from the five research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $4.1250.

Several equities analysts recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $3.00 price target on shares of Lucid Diagnostics in a report on Thursday, March 26th. Ascendiant Capital Markets lifted their price objective on shares of Lucid Diagnostics from $8.25 to $9.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. BTIG Research reaffirmed a “buy” rating and issued a $2.50 price objective on shares of Lucid Diagnostics in a report on Monday, March 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lucid Diagnostics in a research note on Monday, December 29th. Finally, Wall Street Zen raised shares of Lucid Diagnostics from a “sell” rating to a “hold” rating in a report on Saturday, March 28th.

Lucid Diagnostics Stock Performance

Shares of LUCD stock opened at $1.31 on Friday. Lucid Diagnostics has a 52-week low of $0.95 and a 52-week high of $1.70. The firm has a market capitalization of $232.20 million, a P/E ratio of -1.36 and a beta of 1.24. The stock has a 50 day moving average price of $1.30 and a 200 day moving average price of $1.20.

Lucid Diagnostics (NASDAQ:LUCD) last issued its quarterly earnings data on Thursday, March 26th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The company had revenue of $1.50 million for the quarter, compared to the consensus estimate of $1.39 million. As a group, sell-side analysts forecast that Lucid Diagnostics will post -0.22 EPS for the current year.

Institutional Trading of Lucid Diagnostics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. XML Financial LLC increased its holdings in Lucid Diagnostics by 24.8% in the first quarter. XML Financial LLC now owns 223,195 shares of the company’s stock valued at $257,000 after buying an additional 44,400 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Lucid Diagnostics during the 4th quarter worth about $246,000. Millennium Management LLC purchased a new stake in shares of Lucid Diagnostics during the 4th quarter worth about $168,000. Abel Hall LLC acquired a new stake in shares of Lucid Diagnostics during the 4th quarter valued at about $33,000. Finally, Squarepoint Ops LLC increased its stake in shares of Lucid Diagnostics by 1,871.7% in the 4th quarter. Squarepoint Ops LLC now owns 342,883 shares of the company’s stock valued at $374,000 after purchasing an additional 325,493 shares in the last quarter. Institutional investors and hedge funds own 74.01% of the company’s stock.

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.